ArticleNPJ precision oncology2025
Integrative analysis reveals prognostic value of cuproptosis and copper hemostasis related genes in immunotherapy for non-small cell lung cancer.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, and it remains challenging to predict immunotherapy responses. This study integrates RNA sequencing data from five NSCLC immunotherapy cohorts to identify three molecular subtypes, with a copper-dependent proliferation subtype showing poor prognosis and an immunosuppressive tumor microenvironment. We developed a prognostic model that stratifies patients into high- and low-risk groups by a machine learning pipeline combining 101 algorithmic models. The low-risk group exhibited higher immune infiltration and better progression-free survival, characterized by activation of immune-related pathways, such as IL-2/STAT5 and IFN-γ signaling. CEACAM5
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.